Researchers reported that patients treated with the wearable system were discharged around five days earlier than those receiving standard hospital-based care
The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process
The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
Collaboration to deliver scalable automation solutions for electronics, semiconductor, medical manufacturing, and intralogistics sectors
Paves way for CNS cancer test rollout
Advanced image-free robotic platform to support greater precision, personalised planning, and improved patient outcomes
The clearance marks a pivotal step forward for the company as it pushes deeper into AI-driven diagnostics and expands its clinical footprint in point-of-care imaging
Investment will support LifeSigns’ global expansion across Southeast Asia and GCC markets
The ultrasound-based AI imaging platform is designed to support rapid fracture detection and soft tissue injury assessment in emergency care settings
Subscribe To Our Newsletter & Stay Updated
